Research Topics
Species | Johan WestinSummaryCountry: Sweden Publications
| Collaborators
|
Detail Information
Publications
Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infectionErik Alestig
Department of Infection and Virology, University of Gothenburg, Gothenburg, Sweden
BMC Infect Dis 11:124. 2011..In the present study, the impact of these mutations on response kinetics and treatment outcome was explored in Caucasian patients...
Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infectionJohan Westin
Department of Infectious Diseases, Goteborg University, Göteborg Sweden
J Viral Hepat 9:235-41. 2002..From that point of view, total abstention ought to be recommended. If this is not achieved, occasional use of alcohol is probably less harmful than daily drinking for patients with low or moderate alcohol consumption...- A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infectionJohan Westin
Department of Infectious Diseases, Goteborg University, Sweden
Scand J Gastroenterol 43:73-80. 2008.... - Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patientsJohan Westin
Department of Infectious Diseases, Sahlgrenska University Hospital Ostra, Goteborg University, SE 416 85 Goteborg, Sweden
J Hepatol 37:837-42. 2002..Its influence on disease progression is only partially understood. The aim of this study was to evaluate the impact of steatosis on fibrosis progression over time in relation to HCV genotype... - Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infectionJ Westin
Department of Infectious Diseases, Sahlgrenska University Hospital, Goteborg, Sweden
J Viral Hepat 14:29-35. 2007..Patients infected with genotype 3, on the other hand, should be offered early antiviral treatment... 
Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?Asa Alsiö
Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden
Clin Infect Dis 50:e22-5. 2010..Suboptimal drug concentrations may thus contribute to lack of response to therapy in patients with infection due to HCV genotype 2/3...- Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis CGalia Askarieh
Department of Infectious Diseases, University of Gothenburg, Sweden
Hepatology 51:1523-30. 2010..CONCLUSION: In patients with chronic hepatitis C, low levels of intrahepatic and systemic IP-10 predict a favorable first-phase decline of HCV RNA during therapy with pegylated interferon and ribavirin for genotypes of HCV... - Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infectionMartin Lagging
Department of Infectious Diseases, Goteborg University, Goteborg, Sweden
Hepatology 47:1837-45. 2008..0001). CONCLUSION: Peginterferon/ribavirin treatment for 12 weeks in HCV genotype 2/3 infection is overall inferior to 24 weeks of treatment but may be useful in some patients with a rapid initial clearance of virus... - Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virusMagnus Lindh
Department of Infectious Diseases, University of Gothenburg, Sweden
J Infect Dis 203:1748-52. 2011..The results indicate that IL28B gene testing may identify patients carrying genotype 2 or 3 who could benefit from extended treatment... - IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infectionMartin Lagging
Department of Infectious Diseases, University of Goteborg, Sweden
Hepatology 44:1617-25. 2006..Thus, pretreatment IP-10 analysis may prove helpful in decision-making regarding pharmaceutical intervention... - Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infectionMagnus Lindh
Department of Infection and Virology, Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
J Clin Microbiol 45:2439-45. 2007..On the basis of these findings, we propose a model of tailored treatment which takes into account the second-phase slope and the amount of HCV RNA after 21 days of treatment... - Access to a polymerase chain reaction assay method targeting 13 respiratory viruses can reduce antibiotics: a randomised, controlled trialRobin Brittain-Long
Department of Infectious Diseases, Sahlgrenska University Hospital, Smörslottsgatan 1, Gothenburg, Sweden
BMC Med 9:44. 2011.... - Progression of fibrosis in untreated patients with hepatitis C virus infectionL Martin Lagging
Department of Clinical Virology, Goteborg University, Goteborg, Sweden, Department of Infectious Diseases, Goteborg University, Sweden
Liver 22:136-44. 2002..If moderate interface hepatitis early in the course of the disease is followed by less interface hepatitis later there is less fibrosis; and if moderate interface hepatitis persists, there is more fibrosis eventually... - Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage timeL Martin Lagging
Department of Clinical Virology, Goteborg University, Goteborg, Sweden
J Clin Microbiol 40:4224-9. 2002..0 years) and 4.41 for the sera obtained at the time of the second biopsy (median storage time, 6.6 years) compared to 5.96, the median for 102 different routine clinical patient samples... - Seasonal variations of 15 respiratory agents illustrated by the application of a multiplex polymerase chain reaction assayRobin Brittain-Long
Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden
Scand J Infect Dis 44:9-17. 2012..We have assessed the detection rate of a multiplex real-time polymerase chain reaction (PCR) test, with emphasis on epidemiology and seasonal distribution of the most common respiratory tract infections... - Rectal swabs can be used for diagnosis of viral gastroenteritis with a multiple real-time PCR assayLars Gustavsson
Department of Infectious Diseases Clinical Virology, Sahlgrenska University Hospital, Guldhedsgatan 10B, SE 413 46 Gothenburg, Sweden
J Clin Virol 51:279-82. 2011..Viral agents, especially norovirus, are the most common cause of nosocomial spread of epidemic gastroenteritis (GE). Rapid and reliable detection of these agents could reduce the risk of outbreaks... - Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markersSara Islam
Department of Infectious Diseases, , Sweden
Scand J Gastroenterol 40:867-72. 2005..CONCLUSION: An index using routinely available biochemical markers can with a high degree of accuracy discriminate patients with from those without hepatitis C-related cirrhosis... - Prospective evaluation of a novel multiplex real-time PCR assay for detection of fifteen respiratory pathogens-duration of symptoms significantly affects detection rateRobin Brittain-Long
Department of Infectious Diseases, Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden
J Clin Virol 47:263-7. 2010..We have evaluated a multiplex real-time PCR method for the detection of 13 respiratory viruses and 2 bacteria (Mycoplasma and Chlamydophila) in a clinical setting... - The impact of viral respiratory tract infections on long-term morbidity and mortality following lung transplantation: a retrospective cohort study using a multiplex PCR panelJesper Magnusson
Department of Internal Medicine Respiratory Medicine and Allergology, Institute of Medicine, Sahlgrenska University Hospital, Goteborg, Sweden
Transplantation 95:383-8. 2013..The objective of this study was to investigate the development of bronchiolitis obliterans syndrome and graft loss after LTX in relation to the presence of respiratory viruses during the first year after LTX... - Venous lactate levels can be used to identify patients with poor outcome following community-onset norovirus enteritisLars Gustavsson
Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Scand J Infect Dis 44:782-7. 2012..The objective was to determine the frequency and association with mortality of elevated lactate levels in patients with community-onset NVE... - Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infectionJonas Soderholm
Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden
PLoS ONE 8:e56991. 2013..The aim of the present study was to assess the utility of CD26 as a biomarker for treatment outcome in chronic hepatitis C and to define its association with HCV-specific T cells... - Neutralization of pseudotyped vesicular stomatitis virus expressing hepatitis C virus envelope glycoprotein 1 or 2 by serum from patientsL Martin Lagging
Department of Clinical Virology, Goteborg University, Guldhedsgatan 10B, S 413 46 Goteborg, Sweden
J Infect Dis 185:1165-9. 2002.... - Multiplex real-time PCR for detection of respiratory tract infectionsRobin Brittain-Long
Department of Infection, The Sahlgrenska Academy, Goteborg University, 416 85 Goteborg, Sweden
J Clin Virol 41:53-6. 2008..Broad diagnostics of respiratory infection by molecular assays has not yet won acceptance due to technical difficulties and high costs... - Liver cirrhosis in Iceland and Sweden: incidence, aetiology and outcomesSteingerdur Anna Gunnarsdottir
Department of Internal Medicine, Section of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden
Scand J Gastroenterol 44:984-93. 2009..The incidence and mortality of liver cirrhosis in Iceland has been reported to be the lowest in the Western world. There are very few data on aetiology, incidence and prognosis among cirrhotics in Sweden... - Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infectionAna I Romero
Department of Virology, , , Sweden
J Infect Dis 194:895-903. 2006..CONCLUSION: Baseline IP-10 levels are predictive of the response to HCV treatment... - Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trialHans Orlent
Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands
J Hepatol 45:539-46. 2006..The observed ALT response did not translate in a significant histological improvement after 6 months treatment... - Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis CJohan Westin
Hepatology 45:1333-4; author reply 1334. 2007 - Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infectionMartin Lagging
Hepatology 48:695. 2008 - Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6Esther Lukasiewicz
Hepatology 45:258-9. 2007